FDA widens use of leucovorin without new trial datanews2026-03-10T13:00:12+00:00March 10th, 2026|Endpoints News|
Xenon gets Phase 3 win with epilepsy drug, setting up FDA approval filingnews2026-03-09T15:04:48+00:00March 9th, 2026|Endpoints News|
Bristol Myers says second CELMoD succeeds in Phase 3news2026-03-09T14:33:32+00:00March 9th, 2026|Endpoints News|
Roche’s big-hope breast cancer drug fails in crucial first-line trialnews2026-03-09T08:26:14+00:00March 9th, 2026|Endpoints News|
FDA official questions need for advisory committeesnews2026-03-06T01:46:00+00:00March 6th, 2026|Endpoints News|
Roche partner Zealand posts Phase 2 data for amylin obesity drugnews2026-03-05T20:19:31+00:00March 5th, 2026|Endpoints News|
Helus Pharma’s stock slides after psychedelic drug data face questions over dosingnews2026-03-05T19:40:48+00:00March 5th, 2026|Endpoints News|
Merck KGaA drops two cancer trials on assets from SpringWorks dealnews2026-03-05T14:43:11+00:00March 5th, 2026|Endpoints News|
FDA puts PepGen’s Phase 2 muscle disease trial on partial holdnews2026-03-05T12:02:30+00:00March 5th, 2026|Endpoints News|
BIO chief still backs FDA’s Makary despite ‘head-scratcher’ decisionsnews2026-03-04T15:49:33+00:00March 4th, 2026|Endpoints News|
